Kalytera’s cannabidiol (CBD) compound efficiently prevents graft-versus-host disease (GVHD) in patients receiving bone marrow transplants from matched unrelated donors, interim data from a Phase…
News
Using a combination of CAR T-cell therapies to target different cancer molecules appears to be a feasible and promising way of treating relapsed or refractory…
People with monoclonal gammopathy of undetermined significance (MGUS) placed at low- or intermediate-risk of progression to multiple myeloma can develop that cancer within five…
Evomela, an injectable formulation of melphalan, is now available in China as a high-dose conditioning therapy for people with multiple myeloma who will…
KappaMab (MDX-1097), a new monoclonal antibody that binds to the kappa myeloma antigen, has a favorable safety profile in multiple myeloma patients with excess kappa…
Although triple therapies with Revlimid (lenalidomide) should be prioritized in patients with relapsed or refractory multiple myeloma (RRMM), combining this therapy with…
Aiming to both inspire the multiple myeloma community and raise money to accelerate treatments, members of Moving Mountains for Multiple Myeloma (MM4MM) recently traversed…
A new video series by the American Journal of Managed Care (AJMC) features experts discussing issues related to multiple myeloma treatment. Called “…
The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow, blood, or tissue sample —…
A Phase 1 trial evaluating Teneobio’s bispecific antibody TNB-383B as a treatment for multiple myeloma has started dosing patients. This safety and tolerability trial…
